Interim analysis in 188 patients with HER2-positive gastric/GEJ cancer after trastuzumab: anbenitamab plus chemotherapy improved PFS (median 7.1 vs 2.7 months; HR 0.25) and OS (19.6 vs 11.5 months; HR 0.29) vs chemotherapy; grade ≥3 TRAEs 60% vs 45%.
RCTn = 188
Liu et al. Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial